Vidac Pharma (Xetra:T9G)

Executive Summary

Vidac Pharma is an Israeli clinical-stage biopharmaceutical company pioneering metabolic reprogramming therapies for oncology and onco-dermatology. Its platform targets cellular metabolism to reverse the cancer cascade, with lead programs in actinic keratosis (AK) and solid tumors. The company’s patented small-molecule candidates aim to modulate metabolic pathways and restore normal cellular differentiation, offering a novel approach to cancer treatment. Vidac is publicly traded on Xetra under ticker T9G and has advanced its lead candidate, VPC-001, into Phase 2 clinical trials for AK, a common precancerous skin condition. The AK market is substantial, driven by an aging population and increasing UV exposure, and current treatments are limited by efficacy and tolerability. If successful, Vidac’s therapy could capture significant market share. Additionally, the company is exploring the potential of its platform in solid tumors, with preclinical data supporting further development. Vidac’s focus on metabolic modulation differentiates it from competitors and positions it as a key player in the emerging field of cancer metabolism.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 top-line data for VPC-001 in actinic keratosis45% success
• Q2 2027Initiation of Phase 2 trial in solid tumors55% success
• Q3 2026Strategic partnership or licensing deal for VPC-00130% success